1451 related articles for article (PubMed ID: 32654464)
1. [Maintenance therapy following CD19 CAR-T treatment for relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
Jiang YL; Li Q; Pu YD; Jiang YY; Yuan T; Deng Q; Li YM; Han MZ; Zhai WH
Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):495-501. PubMed ID: 32654464
[No Abstract] [Full Text] [Related]
2. Donor-derived CD19 CAR-T Cells versus Chemotherapy Plus Donor Lymphocyte Infusion for Treatment of Recurrent CD19-positive B-ALL After Allogeneic Hematopoietic Stem Cell Transplantation.
Tan X; Wang XQ; Zhang C; Zhao XL; Yao H; Chen G; Ma YY; Wen Q; Gao L; Gao L; Kong PY; Shen Y; Zhang X; Lou SF
Curr Med Sci; 2023 Aug; 43(4):733-740. PubMed ID: 37330456
[TBL] [Abstract][Full Text] [Related]
3. [Allogeneic donor-derived CD19 CAR-T therapy of relapsed B-cell acute lmphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
Ma RZ; He Y; Yang DL; Wei JL; Pang AM; Jiang EL; Wang JX; Han MZ; Zhang RL; Feng SZ
Zhonghua Xue Ye Xue Za Zhi; 2021 May; 42(5):383-389. PubMed ID: 34218580
[No Abstract] [Full Text] [Related]
4. Donor Hematopoietic Stem Cell/Lymphocyte Maintenance Treatment After CAR T-Cell Therapy in Patients With B-Cell Acute Lymphoblastic Leukemia Relapse Following Stem Cell Transplant.
Li Q; Lyu C; Liu M; Wang J; Mou N; Jiang E; Zhang R; Deng Q
Cell Transplant; 2023; 32():9636897231158155. PubMed ID: 36879459
[TBL] [Abstract][Full Text] [Related]
5. CAR19/22 T cell cocktail therapy for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation.
Yan N; Wang N; Wang G; Huang L; Li C; Wang D; Wang J; Huang L; Meng F; Wei J; Chen L; Mao X; Zhou J; Zhang Y; Cao Y
Cytotherapy; 2022 Aug; 24(8):841-849. PubMed ID: 35256277
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic Donor-Derived Anti-CD19 CAR T Cell Is a Promising Therapy for Relapsed/Refractory B-ALL After Allogeneic Hematopoietic Stem-Cell Transplantation.
Hua J; Zhang J; Wu X; Zhou L; Bao X; Han Y; Miao M; Li C; Fu Z; Wu D; Qian W; Qiu H
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):610-616. PubMed ID: 32507386
[TBL] [Abstract][Full Text] [Related]
7. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
Front Immunol; 2021; 12():755549. PubMed ID: 34777367
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of CD19 Chimeric Antigen Receptors T Cells in the Treatment of Relapsed Patients with B Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation].
Chen HR; Zhang Y; Chen P; Liu XD; Huang Q; Zhang J; Li HM; Liu B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1040-1045. PubMed ID: 31418354
[TBL] [Abstract][Full Text] [Related]
9. Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia.
Zhao YL; Liu DY; Sun RJ; Zhang JP; Zhou JR; Wei ZJ; Xiong M; Cao XY; Lu Y; Yang JF; Zhang X; Lu DP; Lu P
Front Immunol; 2021; 12():605766. PubMed ID: 34025637
[TBL] [Abstract][Full Text] [Related]
10. Donor-derived stem cell infusion for sustained pancytopenia after CD19 CAR-T therapy for relapsed patients post allogeneic stem cell transplantation.
Li Y; Li Y; Zhang M; Zhao H; Zhu M; Huang H; Hu Y
Eur J Haematol; 2024 Jan; 112(1):94-101. PubMed ID: 37477866
[TBL] [Abstract][Full Text] [Related]
11. [Safety and efficacy of patients with refractory B-lymphoblastic leukemia treated with anti-CD19 CAR-T cell bridging to allogeneic hematopoietic stem cell transplantation].
Ai H; Yin QS; Wang Q; Fu YW; Wei XD; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2020 Mar; 41(3):239-244. PubMed ID: 32311895
[No Abstract] [Full Text] [Related]
12. Donor-derived CAR-T Cells Serve as a Reduced-intensity Conditioning Regimen for Haploidentical Stem Cell Transplantation in Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: Case Report and Review of the Literature.
Zhang C; Kong PY; Li S; Chen T; Ni X; Li Y; Wang M; Liu Y; Gao L; Gao L; Peng XG; Sun AH; Wang P; Yang Z; Zhang X; Qian C
J Immunother; 2018; 41(6):306-311. PubMed ID: 29864079
[TBL] [Abstract][Full Text] [Related]
13. Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation.
Chen Y; Cheng Y; Suo P; Yan C; Wang Y; Chen Y; Han W; Xu L; Zhang X; Liu K; Chang L; Xiao L; Huang X
Br J Haematol; 2017 Nov; 179(4):598-605. PubMed ID: 29076142
[TBL] [Abstract][Full Text] [Related]
14. [Safety and efficacy of donor-derived chimeric antigen receptor T-cell therapy in patients with relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
Zhuo YQ; Tu SF; Zhou X; Yang JL; Zhou LJ; Huang R; Huang YX; Li MF; Jin B; Wang B; Li SQ; Yuan ZT; Zhang LH; Liu L; Wang SB; Li YH
Zhonghua Xue Ye Xue Za Zhi; 2024 Jan; 45(1):74-81. PubMed ID: 38527842
[No Abstract] [Full Text] [Related]
15. Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation.
Cao XY; Li JJ; Lu PH; Liu KY
Int J Hematol; 2022 Sep; 116(3):315-329. PubMed ID: 35737192
[TBL] [Abstract][Full Text] [Related]
16. Case report: Two pediatric cases of long-term leukemia-free survival with relapsed acute T-lymphoblastic leukemia treated with donor CD7 CAR-T cells bridging to haploidentical stem cell transplantation.
Song Y; Liu Z; Wang Q; Gao K; Wu T
Front Immunol; 2024; 15():1333037. PubMed ID: 38481998
[TBL] [Abstract][Full Text] [Related]
17. Low Level Donor Chimerism of CD19 CAR-T Cells Returned to Complete Donor Chimerism in Patients with Relapse After Allo-Hematopoietic Stem Cell Transplant.
Li Q; Mu J; Yuan J; Yang Z; Wang J; Deng Q
Onco Targets Ther; 2020; 13():11471-11484. PubMed ID: 33204102
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic, donor-derived, second-generation, CD19-directed CAR-T cells for the treatment of pediatric relapsed/refractory BCP-ALL.
Del Bufalo F; Becilli M; Rosignoli C; De Angelis B; Algeri M; Hanssens L; Gunetti M; Iacovelli S; Li Pira G; Girolami E; Leone G; Lazzaro S; Bertaina V; Sinibaldi M; Di Cecca S; Iaffaldano L; Künkele A; Boccieri E; Del Baldo G; Pagliara D; Merli P; Carta R; Quintarelli C; Locatelli F
Blood; 2023 Jul; 142(2):146-157. PubMed ID: 37172203
[TBL] [Abstract][Full Text] [Related]
19. Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.
Cai B; Guo M; Wang Y; Zhang Y; Yang J; Guo Y; Dai H; Yu C; Sun Q; Qiao J; Hu K; Zuo H; Dong Z; Zhang Z; Feng M; Li B; Sun Y; Liu T; Liu Z; Wang Y; Huang Y; Yao B; Han W; Ai H
J Hematol Oncol; 2016 Nov; 9(1):131. PubMed ID: 27887660
[TBL] [Abstract][Full Text] [Related]
20. CD19+ lineage chimerism, an early biomarker after anti-CD19 CAR-T cell therapy in patients previously receiving a hematopoietic stem cell transplantation.
Martínez-Romera I; Galán-Gómez V; González-Martínez B; Guerra García P; San Román Pacheco S; Corral Sánchez D; Mozo Del Castillo Y; Bueno Sánchez D; Sisinni L; González Guerrero A; Castellano Dámaso S; Sánchez Zapardiel E; Ruz Caracuel B; Balas Pérez A; Pérez-Martínez A
Front Immunol; 2022; 13():960412. PubMed ID: 36003375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
